Raymond James Financial’s ADMA Biologics ADMA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.4M Sell
339,443
-27,671
-8% -$256K ﹤0.01% 3095
2026
Q2
$3.07M Sell
367,114
-283,875
-44% -$2.59M ﹤0.01% 3158
2026
Q1
$5.87M Sell
650,989
-362,753
-36% -$5.72M ﹤0.01% 2462
2025
Q4
$18.5M Sell
1,013,742
-238,054
-19% -$4.01M 0.01% 1508
2025
Q3
$18.4M Sell
1,251,796
-270,249
-18% -$4.63M 0.01% 1474
2025
Q2
$27.7M Buy
1,522,045
+202,242
+15% +$4.12M 0.01% 1132
2025
Q1
$26.2M Buy
1,319,803
+207,528
+19% +$3.59M 0.01% 1108
2024
Q4
$19.1M Hold
1,112,275
– – 0.01% 1354

Other funds holding ADMA

Raymond James Financial's ADMA Position: Q3 2026 in Review

Raymond James Financial reduced its ADMA Biologics (ADMA) stake by 7.5% in Q3 2026, selling an estimated $256K and leaving 339,443 shares worth $3.4M. The position accounts for ﹤0.01% of the portfolio, ranked #3095.

Raymond James Financial first reported a position in ADMA in Q4 2024 and has held it in 8 quarters since. The position peaked at $27.7M in Q2 2025. 329 funds tracked by Wall St. Rank hold ADMA as of Q3 2026.

  • Raymond James Financial held 339,443 shares of ADMA Biologics worth $3.4M as of Q3 2026.
  • Raymond James Financial sold 27,671 ADMA Biologics shares in Q3 2026, an estimated $256K.
  • ADMA Biologics made up ﹤0.01% of Raymond James Financial's portfolio in Q3 2026, its #3095 holding.
  • Raymond James Financial first reported a position in ADMA Biologics in Q4 2024 and has held it in 8 quarters since.
  • Raymond James Financial's ADMA Biologics position peaked at $27.7M in Q2 2025.
  • 329 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2026.

Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.